# RNN 1st Gen Model Zoetis Inc. Pharmaceutical preparations

Prediction models:
Subscribe >> Deal exit on
May 3, 2018
Deal entry on
May 3, 2018
1.50%Expected margin
80.43% successful of 46 deals
$ 84.40 Last close price
at 18-may-2018

ZTS

Model's trade recommendations No return for period yet

13.53% Annual return

$38.77B Market Cap

β 0.97  

ZTS

Model (following trade recommendations)

ZTS

Underlying stock

S&P 500

Index
Return for period
-1.06%
1.78%
52wk return 17.54%
39.94%
16.82%
52wk Range
59.73—85.97
2000.54—2399.63
Sortino ratio 2.95
Sharpe ratio 1.45
Norm. RMSE 0.57%
Downside risk 4.33%
Volatility 8.82%
  • 0.50 (0.63%) Div (Yield)
  • BUY Analysts consensus recommendation

Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Zoetis Inc. (ZTS) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for ZTS model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 484M
P/E 30.50
Shares Outstanding 485M
% Held by Insiders 0.35%
% Held by Institutions 92.60%
EPS (last reported FY) $2.40
EPS (last reported Q) $0.75
EPS, estimated (last reported Q) $0.70
Total revenues $5 B
Net income $1 B